Bridging the Gap: Scaling Affordable and High-Quality MedTech Solutions in India

The gathering's premise is deceptively simple: innovation that never reaches a patient is not innovation at all. The harder question is whether access, affordability, and quality can be engineered to move together rather than trade off against each other.

The arithmetic of access

India ranks among the fastest-growing MedTech markets worldwide, anchored by a mature manufacturing base and an emerging innovation ecosystem. Yet the distance between what the sector can produce and what patients actually receive remains wide — across Indian districts and across the low- and middle-income countries that increasingly import Indian-made devices.

The summit's organizing principle is that access paired with poor quality accomplishes nothing: it fails to build trust and fails to improve outcomes. Sessions will work through how to deliver consistent standards of safety and efficacy from Tier 1 hospital corridors into rural districts, where infrastructure, training, and supply chains strain under demand. The conversation extends outward to export markets where India hopes to position itself as a high-volume, high-quality supplier rather than a budget-tier one.

The policy lever

Government intent is the clearest variable in the equation. The sector is one of the named pillars of the Make in India program, aligned with the Viksit Bharat 2047 roadmap. A cluster of initiatives — Biopharma Shakti, the Anusandhan National Research Foundation (ANRF), the MAHA MedTech Mission, and the Promotion of Research and Innovation in Pharma MedTech (PRIP) scheme — is engineered to catalyze a shift from low-cost contract manufacturing toward high-value MedTech innovation.

The objective is operational rather than rhetorical: domestic capability that yields regulatory-grade products, research collaborations in emerging therapeutic areas, and an investment climate that rewards depth over volume.

What happens in the room

The 18th edition assembles a broad coalition. Policymakers and drug regulators will sit with industry leaders from MedTech companies, alongside researchers, academicians, healthcare-IT professionals, and data scientists. International associations, startups, incubators, hospital systems, and the consulting layer that orbits them round out the roster.

Working sessions target four operational choke points: regulatory harmonization across jurisdictions, ease of doing business in India, faster routes from approval to adoption, and the cross-sector partnerships required to make those routes durable. Parallel coverage from IDTechEx on wearables in assistive healthcare and recent government remarks marking twelve years of the Swasth Bharat initiative point to where adjacent momentum is building.

The projection worth tracking: whether the USD 16 billion figure moves materially against the USD 680 billion denominator over the next policy cycle. That ratio, more than any summit communique, will signal whether access, affordability, and quality are converging — or merely being aligned on paper.